Global Commercial Launch Preparations Underway for First Potential Approval Towards Building Specialty Cardiovascular Franchise Company Recently Launched Unbranded Disease Awareness Campaign “HCM ...

HFpEF is most common among older adults and women. This article discusses the symptoms, causes, diagnosis, and treatment of heart failure with preserved ejection fraction. If you have HFpEF, your ...

The findings, he added, support current guidelines that encourage physicians to “leverage” episodes of worsening heart failure, and heart failure hospitalizations in particular, as a good time to ...

Javed Butler, MD, MPH, MBA, discusses the additional benefits of combining finerenone with sodium-glucose cotransporter-2 inhibitors for treating heart failure (HF) with midrange ejection fraction ...

Duke-NUS scientists and their collaborators have discovered a potential new treatment for heart failure with preserved ...

We describe the epidemiology, clinical features, treatment strategies, and in‐hospital outcomes in patients ... Smooth curves of the odds of prevalence of HFrEF and HFmrEF compared with HFpEF across ...

Duke-NUS scientists and their collaborators have discovered a potential new treatment for heart failure ... heart failure with reduced ejection fraction (HFrEF), typically observed in hypertensive ...

Duke-NUS scientists and their collaborators have discovered a potential new treatment for heart failure with preserved ejection fraction (HFpEF), a type of heart disease that is notoriously difficult ...

HFrEF= Heart Failure Reduced Ejection Fraction; HFpEF= Heart Failure Preserved Ejection Fraction; CKD= Chronic Kidney Disease; CVD + DM= Cardiovascular Disease with Diabetes Mellitus. This is an ASCO ...

Cardurion is developing next-generation therapeutics for the treatment of cardiovascular diseases, including: PDE9 inhibitor, CRD‑750, is being evaluated in two Phase 2 clinical trials in 640 patients ...